Previous 10 | Next 10 |
home / stock / biib / biib articles
LOS ANGELES, May 29, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class a...
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investo...
SAN DIEGO, May 25, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biog...
SAN DIEGO, May 24, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of persons and enti...
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Biogen Inc. (NASDAQ:BIIB)? Did you purchas...
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notif...
LOS ANGELES, May 23, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class a...
SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Biogen class action lawsuit seeks to represe...
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of im...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...